Laval, Québec, CANADA – August 28, 2012 – Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ.NEPT - TSX.NTB) and Acasti Pharma Inc. (“Acasti”) (TSX-V.APO) are pleased to announce the extension of the relationship with The Howard Group as companies’ investor relations consultant.

"We are very happy to have the Howard Group supporting our Investor Relations efforts," said Andre Godin, CFO of Neptune. "The Howard Group is aligned financially through its share ownership of Neptune and Acasti. The Howard Group knows our Companies well through a relationship of more than five years in total."

Since 1988, the Howard Group has provided comprehensive investor and financial relations, business development solutions and in-depth strategic planning to public companies. The Howard Group is associated with the Insight Limited Partnership II, which invests in micro and small cap companies. Traditional and new online initiatives will be directed at the investment community and investing public on behalf of Neptune and Acasti to increase the following and participation of the market in those two Companies.

The term of the IR Agreement is for a period of 12 months. In addition to a fee of $6,000 per month, The Howard Group has been granted options to purchase an aggregate total of 50,000 common shares of Neptune at a price of $5.00 per share and 50,000 common shares of Acasti Pharma at a price of $2.50. The options will vest in equal amounts over an 18 month term. The Agreement and the options granted are subject to the board of directors and regulatory approvals.

About Acasti Pharma Inc.
Acasti Pharma (TSXV: APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma’s proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm Inc.